Clinical Trials on Peripheral Cholangiocarcinoma in China

Total 706 results

Shanghai Zhongshan Hospital

Unknown

Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)

Advanced Intrahepatic Cholangiocarcinoma

China
Hutchmed

Recruiting

Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Advanced Intrahepatic Cholangiocarcinoma

China
Shanghai Zhongshan Hospital

Recruiting

PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment

Cholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer

Recruiting

Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-013)

Cholangiocarcinoma Non-resectable

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-012)

Cholangiocarcinoma Non-resectable

China
Hua Li

Recruiting

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

China
Shanghai Zhongshan Hospital

Active, not recruiting

Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma (CCGLC-009)

Cholangiocarcinoma Non-resectable

China
Zhongda Hospital

Completed

REMS Combined With TAI for Unresectable HC

Unresectable Hilar Cholangiocarcinoma

China
Shanghai Zhongshan Hospital

Active, not recruiting

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
Zhejiang University

Recruiting

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma by AJCC V8 Stage

China
Shanghai Zhongshan Hospital
Shenzhen University General Hospital; Xuhui Central Hospital, Shanghai; Minhang... and other collaborators

Recruiting

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Cholangiocarcinoma, Intrahepatic

China
Zhiyong Huang

Not yet recruiting

Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Intrahepatic Cholangiocarcinoma

China
Fudan University

Recruiting

Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Newish Technology (Beijing) Co., Ltd.
Peking Union Medical College Hospital

Recruiting

Clinical Trial of Autologous Tcm Immunotherapy in ICC

Cholangiocarcinoma

China
Fudan University

Withdrawn

GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC

Intrahepatic Cholangiocarcinoma

China
Eastern Hepatobiliary Surgery Hospital

Unknown

Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Shen Feng

Active, not recruiting

Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC

Intrahepatic Cholangiocarcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Eastern Hepatobiliary Surgery Hospital

Unknown

Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients

Intrahepatic Cholangiocarcinoma

China
Beijing Tsinghua Chang Gung Hospital

Recruiting

Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC

Intrahepatic Cholangiocarcinoma

China
Fudan University

Recruiting

HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

Intrahepatic Cholangiocarcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Shanghai Zhongshan Hospital

Recruiting

Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Fudan University

Recruiting

TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Hutchmed

Completed

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

Intrahepatic Cholangiocarcinoma

China
Xuhua Duan

Recruiting

An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

Extrahepatic Cholangiocarcinoma

China
Binkui Li

Recruiting

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Yunfei Yuan

Recruiting

HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Shi Ming

Recruiting

HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC

Intrahepatic Cholangiocarcinoma

China
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Neoadjuvant PDT in the Treatment of Cholangiocarcinoma

Cholangiocarcinoma Resectable

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

Intrahepatic Cholangiocarcinoma

China
Sun Yat-sen University

Completed

HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Shi Ming

Unknown

HAIC Versus Systemic Chemotherapy for Unresectable ICC

Intrahepatic Cholangiocarcinoma

China
Nanfang Hospital, Southern Medical University

Recruiting

Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Qilu Hospital of Shandong University
BeiGene

Recruiting

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Second Affiliated Hospital, School of Medicine,...
The First Affiliated Hospital of Zhengzhou University; The Affiliated Tumor...

Recruiting

Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients With Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Zhongda Hospital

Recruiting

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Cholangiocarcinoma

China
Tongji Hospital

Recruiting

A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC (CCGLC-005)

Intrahepatic Cholangiocarcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Zhengang Yuan

Unknown

Bortezomib in Intrahepatic Cholangiocellular Carcinoma

Intrahepatic Cholangiocarcinoma

China
Peking University

Recruiting

Biliary Drainage Plus HAIC in Locally Advanced pCCA

Perihilar Cholangiocarcinoma

China
Beijing Tsinghua Chang Gung Hospital

Completed

Extent of Intrahepatic Infiltration of Perihilar Cholangiocarcinoma

Perihilar Cholangiocarcinoma

China

3

Subscribe